Acelyrin, INC Form 4 insider transactions

Alumis and ACELYRIN reaffirm their commitment to merge in an all-stock transaction, creating a leading clinical-stage biopharma company focused on immune-mediated diseases.

Alumis and ACELYRIN reaffirm their commitment to merge in an all-stock transaction, creating a leading clinical-stage biopharma company focused on immune-mediated diseases.

ACELYRIN, INC. has determined that an unsolicited indication of interest from Concentra Biosciences is not expected to result in a superior proposal to their planned merger with Alumis Inc., and continues to recommend stockholder support for the Alumis transaction.

ACELYRIN, INC. has confirmed an unsolicited indication of interest from Concentra Biosciences to acquire all outstanding shares for $3.00 per share in cash, plus a contingent value right, while the company is already in the process of merging with Alumis Inc.

Alumis and ACELYRIN are merging in a stock transaction, creating a combined entity with a diversified pipeline and stronger financial position.

Alumis and ACELYRIN are merging in an all-stock transaction to create a combined company with a diversified late-stage immunology pipeline and stronger financial resources.

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement, subject to stockholder and regulatory approvals, with the goal of creating a stronger combined entity.

Alumis and ACELYRIN have announced a proposed merger, subject to stockholder and regulatory approvals, with the goal of creating a stronger combined company with a robust clinical pipeline.

ACELYRIN and Alumis have announced a definitive agreement to merge in an all-stock transaction, aiming to create a leading company focused on developing therapies for immune-mediated diseases.

Alumis and ACELYRIN are merging in an all-stock transaction to form a late-stage clinical biopharmaceutical company focused on immune-mediated diseases, with a combined cash position of approximately $737 million.

Alumis and ACELYRIN are merging in an all-stock transaction to create a late-stage clinical biopharma company focused on immune-mediated diseases.

Alumis and ACELYRIN have announced a merger, creating a combined entity with approximately $737 million in cash to fund operations into 2027 and advance their respective clinical programs.

Alumis and ACELYRIN are merging in an all-stock transaction to create a late-stage clinical biopharma company focused on immune-mediated diseases, with a combined cash position providing runway into 2027.

Acelyrin's Chief Medical Officer, Shephard Mpofu, was granted 125,000 restricted stock units (RSUs) that vest over three years.

Acelyrin CEO Mina Kim acquired 575,000 restricted stock units and 4,000 shares through the employee stock purchase plan, while disposing of 689,739 shares.

Acelyrin's Chief Legal Officer, Amar Murugan, acquired 125,000 shares of common stock through the vesting of restricted stock units.

Acelyrin's Chief Legal Officer, Amar Murugan, was granted 525,000 employee stock options at an exercise price of $4.73 on November 25, 2024.

Gil M Labrucherie, CFO and CBO of Acelyrin, Inc., acquired 150,000 employee stock options on August 31, 2024, according to a Form 4 filing.

Director Daniel J. Becker sold one share of Acelyrin, Inc. to AI Acel LLC, an affiliate of Access Industries, Inc., in an off-market transaction to comply with Hart-Scott-Rodino Act requirements.

Director Beth C. Seidenberg acquired 92,158 stock options in Acelyrin, Inc. on June 7, 2024.

Director Bruce C. Cozadd reports acquisition of 92,158 stock options in Acelyrin, Inc.

Director Daniel J. Becker acquired stock options in Acelyrin, Inc. on June 7, 2024.

Director Henry O. Gosebruch acquired stock options in Acelyrin, Inc. on June 7, 2024.

Director Patrick Machado acquired stock options for 92,158 shares of Acelyrin, Inc. at an exercise price of $4.46 on June 7, 2024.

Director Dawn Svoronos reports the acquisition of stock options in Acelyrin, Inc.

Director Lynn A. Tetrault reports the acquisition of stock options in Acelyrin, Inc.

Acelyrin's CEO, Mina Kim, reports the acquisition of stock options in the company.

Sanam Pangali, CLO & Head of People at Acelyrin, Inc., acquired stock options for 328,860 shares of common stock on May 23, 2024.

Shephard Mpofu, Chief Medical Officer of Acelyrin, Inc., was granted stock options to purchase 328,860 shares of common stock on May 23, 2024.

Melanie Gloria, Chief Operating Officer of Acelyrin, Inc., reports the acquisition of stock options.